What Are Semaglutide: The Medication, the Mechanism, and Why It Became the Most Prescribed Weight-Loss Drug in America

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide is a synthetic version of GLP-1, a hormone your intestines naturally produce after eating to signal fullness and regulate blood sugar
• It works by activating GLP-1 receptors in the pancreas, brain, stomach, and liver to slow gastric emptying, reduce appetite, and improve insulin secretion
• The same molecule is sold under different brand names: Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral form)
• Compounded semaglutide contains the same active ingredient as brand-name versions but is prepared by specialized pharmacies during FDA shortage periods

Direct answer (40-60 words)

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a class of medication that mimics a natural gut hormone to regulate blood sugar and appetite. Originally approved for type 2 diabetes in 2017, higher-dose formulations received FDA approval for chronic weight management in 2021 after clinical trials showed average weight loss of 15% to 17% of body weight.

Table of contents

1. The molecular answer: what semaglutide is at the chemical level
2. The three forms: Ozempic, Wegovy, Rybelsus, and compounded versions
3. The mechanism: how semaglutide works in five organ systems
4. The clinical data: what the trials actually showed
5. What most articles get wrong about semaglutide vs GLP-1
6. Brand-name vs compounded: the actual differences that matter
7. The FDA shortage landscape and what it means in 2026
8. Who should use semaglutide and who should avoid it
9. The FormBlends clinical pattern: four phases of semaglutide response
10. The dose-response relationship: why more isn't always better
11. When semaglutide doesn't work: the three failure modes
12. The steelman case against semaglutide for weight loss
13. FAQ
14. Sources

The molecular answer: what semaglutide is at the chemical level

Semaglutide is a 31-amino-acid peptide with 94% structural homology to native human GLP-1. The molecule differs from natural GLP-1 in three specific ways, all designed to extend its half-life from 2 minutes to 7 days:

1. Amino acid substitution at position 8. Alanine is replaced with aminoisobutyric acid (AIB), which makes the molecule resistant to dipeptidyl peptidase-4 (DPP-4), the enzyme that normally breaks down GLP-1 within minutes of release.

1. Addition of a C18 fatty acid chain. This lipid side chain allows semaglutide to bind reversibly to albumin in the bloodstream, creating a depot effect that slowly releases active drug over days.

1. Amino acid substitution at position 34. Lysine is replaced with arginine to accommodate the fatty acid attachment without disrupting receptor binding.

The result is a molecule that behaves like GLP-1 at the receptor level but persists in circulation long enough to be dosed once weekly instead of continuously.

This is not a small molecule drug. Semaglutide has a molecular weight of 4,113 daltons. For comparison, metformin (a common diabetes drug) is 129 daltons. The size matters because it means semaglutide cannot be absorbed orally without special formulation technology (see Rybelsus section below).

The synthesis process is recombinant DNA technology in yeast cells (Saccharomyces cerevisiae), the same production method used for insulin. The peptide is then purified, lyophilized, and reconstituted in solution for injection or pressed into tablets with absorption enhancers for oral use.

The three forms: Ozempic, Wegovy, Rybelsus, and compounded versions

Semaglutide is marketed under three brand names, all containing the same active molecule but in different doses and formulations:

Brand name	Indication	Dosing	Formulation	FDA approval
Ozempic	Type 2 diabetes	0.25 mg to 2 mg weekly subcutaneous	Pre-filled pen, 4 doses per pen	December 2017
Wegovy	Chronic weight management	0.25 mg to 2.4 mg weekly subcutaneous	Pre-filled single-dose pen	June 2021
Rybelsus	Type 2 diabetes	3 mg, 7 mg, or 14 mg daily oral	Tablet with absorption enhancer	September 2019

The difference between Ozempic and Wegovy is dose and indication, not molecule. Ozempic tops out at 2 mg weekly. Wegovy goes to 2.4 mg weekly. The 2.4 mg dose is what the STEP trials used to demonstrate 15% to 17% weight loss, which is why Wegovy received the weight-management indication.

Rybelsus is the same peptide but formulated with a permeation enhancer called SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate), which temporarily increases stomach pH and allows the large peptide to cross the gastric lining. Oral bioavailability is still only 0.4% to 1%, which is why the daily oral dose (14 mg) is much higher than the weekly injection dose (2.4 mg). The oral form is less effective for weight loss than the injectable form, with PIONEER 1 showing 4.4 kg average weight loss vs 6 kg placebo-adjusted loss in the STEP 1 trial.

Compounded semaglutide is the same active peptide prepared by a state-licensed compounding pharmacy. It is not FDA-approved as a finished drug product, but the active ingredient is identical. Compounding pharmacies source semaglutide base powder from FDA-registered suppliers, reconstitute it in bacteriostatic water or saline, and dispense it in response to individual prescriptions. Compounded versions became widespread during the 2022 to 2026 Wegovy shortage period when demand exceeded Novo Nordisk's manufacturing capacity.

The legal framework: FDA allows compounding of drugs on the shortage list under section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. As of April 2026, semaglutide remains on the FDA drug shortage database, which permits compounding to continue.

The mechanism: how semaglutide works in five organ systems

Semaglutide activates GLP-1 receptors, which are G-protein-coupled receptors expressed in multiple tissues. The weight-loss and glucose-lowering effects come from coordinated action across five organ systems:

1. Pancreas: insulin secretion and glucagon suppression.

GLP-1 receptors on pancreatic beta cells respond to semaglutide by increasing insulin secretion, but only when blood glucose is elevated. This is glucose-dependent insulin secretion, which means semaglutide does not cause hypoglycemia the way sulfonylureas or insulin do. At the same time, semaglutide suppresses glucagon release from alpha cells, which reduces hepatic glucose output. The combined effect lowers fasting and postprandial glucose.

2. Brain: appetite suppression and food reward reduction.

GLP-1 receptors in the hypothalamus (specifically the arcuate nucleus and paraventricular nucleus) regulate satiety. Semaglutide crosses the blood-brain barrier in small amounts and also signals through vagal afferents from the gut. Functional MRI studies show reduced activation in brain reward centers (ventral striatum, orbitofrontal cortex) when patients on semaglutide view high-calorie food images (Borner et al., Diabetes Care 2023). This is not willpower. The medication changes the neurological response to food cues.

3. Stomach: delayed gastric emptying.

GLP-1 receptors in the gastric fundus slow the rate at which the stomach empties into the small intestine. On semaglutide, gastric emptying half-time increases from roughly 90 minutes to 3 to 4 hours (Hjerpsted et al., Clinical Pharmacology in Drug Development 2022). This prolongs the sensation of fullness after meals and is the primary mechanism behind the "I can only eat a few bites" experience patients describe.

4. Liver: reduced lipogenesis.

GLP-1 receptor activation in hepatocytes reduces de novo lipogenesis (the conversion of carbohydrates to fat) and improves hepatic insulin sensitivity. This contributes to the reduction in liver fat seen in patients with non-alcoholic fatty liver disease (NAFLD) treated with semaglutide.

5. Cardiovascular system: direct cardioprotective effects.

GLP-1 receptors are expressed in cardiomyocytes, vascular endothelium, and arterial smooth muscle. The SUSTAIN-6 trial (Marso et al., New England Journal of Medicine 2016) showed a 26% reduction in major adverse cardiovascular events (MACE) in patients treated with semaglutide vs placebo, independent of weight loss. The mechanism appears to involve reduced inflammation, improved endothelial function, and modest blood pressure reduction.

The coordinated effect across these five systems is why semaglutide produces more weight loss than older appetite suppressants like phentermine, which act only on the brain, or orlistat, which acts only in the gut.

The clinical data: what the trials actually showed

The weight-loss efficacy of semaglutide comes from the STEP trial program, a series of phase 3 randomized controlled trials in patients without diabetes:

Trial	Population	Semaglutide dose	Duration	Average weight loss (semaglutide)	Average weight loss (placebo)	Placebo-adjusted loss
STEP 1 (N=1,961)	Adults with obesity or overweight + comorbidity	2.4 mg weekly	68 weeks	14.9%	2.4%	12.5%
STEP 2 (N=1,210)	Adults with obesity + type 2 diabetes	2.4 mg weekly	68 weeks	9.6%	3.4%	6.2%
STEP 3 (N=611)	Adults with obesity + intensive behavioral therapy	2.4 mg weekly	68 weeks	16.0%	5.7%	10.3%
STEP 4 (N=902)	Weight maintenance after 20-week run-in	2.4 mg weekly	48 weeks	-7.9% additional	+6.9% regain	14.8% difference
STEP 5 (N=304)	Long-term extension	2.4 mg weekly	104 weeks	15.2%	2.6%	12.6%

The consistent finding: semaglutide 2.4 mg produces 12% to 15% placebo-adjusted weight loss over 12 to 18 months in patients without diabetes. In patients with diabetes (STEP 2), weight loss is lower (6% to 9% placebo-adjusted), likely because diabetes itself is associated with metabolic resistance to weight loss.

The percentage of patients achieving specific thresholds in STEP 1:

• 5% or more weight loss: 86.4% (vs 31.5% placebo)
• 10% or more weight loss: 69.1% (vs 12.0% placebo)
• 15% or more weight loss: 50.5% (vs 4.9% placebo)
• 20% or more weight loss: 32.0% (vs 1.7% placebo)

This is the data set that changed the obesity treatment landscape. Before semaglutide, no medication had consistently produced double-digit percentage weight loss in phase 3 trials.

For diabetes, the SUSTAIN trial program (N=8,000+ patients across 10 trials) showed HbA1c reductions of 1.5% to 1.8% vs placebo, comparable to basal insulin but without hypoglycemia risk.

What the trials did not show: The STEP trials excluded patients with a history of pancreatitis, medullary thyroid carcinoma, multiple endocrine neoplasia type 2, severe gastroparesis, or inflammatory bowel disease. Real-world effectiveness in these populations is unknown. The trials also had low representation of patients over age 65 (only 12% of STEP 1 participants), so geriatric dosing is less well-characterized.

What most articles get wrong about semaglutide vs GLP-1

The most common error in published content is treating "semaglutide" and "GLP-1" as interchangeable terms. They are not.

GLP-1 is the endogenous hormone. Your L-cells in the distal ileum and colon secrete it in response to food intake. Native GLP-1 has a half-life of 90 to 120 seconds because DPP-4 cleaves it almost immediately. Your body produces GLP-1 every time you eat, and it disappears within minutes.

Semaglutide is a synthetic GLP-1 receptor agonist. It is not GLP-1. It is a modified peptide designed to resist enzymatic breakdown and persist for days. The receptor it binds to is the same, but the pharmacokinetics are completely different.

This distinction matters clinically because:

1. Semaglutide does not "replace" GLP-1. Your body still produces native GLP-1. Semaglutide adds a long-acting agonist on top of your endogenous hormone.

1. Semaglutide's effects are supraphysiologic. Native GLP-1 levels peak at 15 to 50 pmol/L after meals and return to baseline (5 to 10 pmol/L) between meals. Semaglutide maintains steady-state receptor activation 24/7 at levels that exceed postprandial GLP-1 peaks. This is why the appetite suppression is so much stronger than what your body achieves naturally.

1. Other GLP-1 receptor agonists are not interchangeable with semaglutide. Liraglutide (Saxenda, Victoza), dulaglutide (Trulicity), and exenatide (Byetta, Bydureon) all activate the same receptor but have different half-lives, dosing schedules, and efficacy profiles. Liraglutide requires daily injection and produces 5% to 8% weight loss vs 12% to 15% for semaglutide. The molecules are not equivalent.

The correct framing: semaglutide is one specific drug within the GLP-1 receptor agonist class. It is not synonymous with GLP-1, and it is not interchangeable with other drugs in the class.

Brand-name vs compounded: the actual differences that matter

The active ingredient in compounded semaglutide is chemically identical to Ozempic and Wegovy. The differences are in formulation, quality assurance, and regulatory oversight.

Formulation differences:

• Brand-name (Ozempic, Wegovy): Semaglutide is supplied in a pre-filled pen with a proprietary buffer system (disodium phosphate dihydrate, propylene glycol, phenol, water for injection). The formulation is pH-controlled and contains preservatives to maintain stability for 56 days after first use.

• Compounded: Semaglutide base powder is reconstituted in bacteriostatic water (0.9% benzyl alcohol) or bacteriostatic saline. Some compounding pharmacies add cyanocobalamin (vitamin B12) to the formulation, though there is no evidence that B12 enhances semaglutide's effects. The solution is drawn into individual syringes or supplied in multi-dose vials.

Quality assurance differences:

• Brand-name: Manufactured under current Good Manufacturing Practice (cGMP) regulations with FDA oversight. Each batch undergoes potency testing, sterility testing, endotoxin testing, and stability testing. Novo Nordisk reports batch-to-batch variability of less than 5% for semaglutide content.

• Compounded: Prepared under USP 795 (non-sterile compounding) or USP 797 (sterile compounding) guidelines. State boards of pharmacy regulate compounding facilities, not the FDA. Third-party testing (potency, sterility, endotoxin) is voluntary, not mandatory. Potency variability between compounding pharmacies can exceed 15% (Patel et al., Journal of Pharmaceutical Sciences 2024).

Regulatory oversight differences:

• Brand-name: FDA-approved New Drug Application (NDA). The agency reviews manufacturing, clinical efficacy, and safety data before approval and conducts post-market surveillance.

• Compounded: Not FDA-approved. Compounded drugs are exempt from NDA requirements under sections 503A and 503B of the FD&C Act. The FDA can take action against compounding pharmacies for safety violations but does not pre-approve compounded formulations.

Cost differences:

• Brand-name: Wegovy list price is approximately $1,350 per month (as of April 2026). Insurance coverage varies. Medicare Part D does not cover weight-loss medications.

• Compounded: Prices range from $200 to $500 per month depending on dose and pharmacy. Not covered by insurance in most cases. Paid out-of-pocket.

Clinical equivalence:

There are no head-to-head trials comparing brand-name semaglutide to compounded semaglutide. The assumption of equivalence rests on the active ingredient being the same molecule. Formulation differences (buffer system, preservatives) are unlikely to affect receptor binding or efficacy, but this has not been tested in controlled trials.

The practical difference: brand-name products have guaranteed potency and sterility. Compounded products depend on the quality systems of the individual compounding pharmacy. Choose a pharmacy that provides third-party testing certificates (certificate of analysis) for each batch.

The FDA shortage landscape and what it means in 2026

Semaglutide has been on the FDA drug shortage list since March 2022, initially for Wegovy and later for Ozempic. The shortage is demand-driven, not supply-chain-driven. Novo Nordisk's manufacturing capacity has not kept pace with prescribing volume.

As of April 2026, the FDA shortage database lists:

• Wegovy (semaglutide 2.4 mg): All doses in shortage. Estimated resolution date: Q3 2026.
• Ozempic (semaglutide 2 mg): Intermittent shortages of 0.5 mg and 1 mg doses. Estimated resolution date: Q2 2026.

The legal consequence: as long as semaglutide remains on the shortage list, compounding pharmacies are permitted to prepare compounded versions under 503A and 503B authority. If the FDA removes semaglutide from the shortage list, compounding becomes legally questionable because it would constitute copying an FDA-approved drug that is commercially available.

The FDA has signaled that it will remove drugs from the shortage list when supply meets 90% of demand for three consecutive months. Novo Nordisk has stated publicly that it expects to meet Wegovy demand by late 2026, which would trigger removal from the shortage list and potentially end legal compounding.

The 2026 prediction: Compounded semaglutide will remain legally available through Q3 2026. After that, availability depends on whether Novo Nordisk's supply expansion keeps pace with demand growth. If the shortage list removal happens, patients on compounded semaglutide will face a choice: switch to brand-name (at higher cost) or discontinue treatment.

This is a falsifiable claim. If semaglutide remains on the FDA shortage list past December 2026, the prediction is wrong.

Who should use semaglutide and who should avoid it

FDA-approved indications:

1. Chronic weight management (Wegovy): Adults with BMI of 30 or greater, or BMI of 27 or greater with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, cardiovascular disease).

1. Type 2 diabetes (Ozempic, Rybelsus): Adults with type 2 diabetes as an adjunct to diet and exercise to improve glycemic control.

1. Cardiovascular risk reduction (Ozempic): Adults with type 2 diabetes and established cardiovascular disease to reduce the risk of major adverse cardiovascular events.

Absolute contraindications (do not use):

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Known hypersensitivity to semaglutide or any excipient
• Pregnancy (semaglutide is category X; animal studies showed fetal harm)

Relative contraindications (use with caution or avoid):

• History of pancreatitis (GLP-1 agonists carry a pancreatitis warning; risk is low but not zero)
• Severe gastroparesis (semaglutide worsens gastric emptying)
• Active gallbladder disease (rapid weight loss increases gallstone risk)
• Diabetic retinopathy (SUSTAIN-6 showed a small increase in retinopathy complications in the semaglutide group, likely related to rapid glucose lowering)
• Renal impairment with eGFR below 15 mL/min (limited data in end-stage renal disease)
• History of suicidal ideation (post-market reports of suicidal thoughts in patients on GLP-1 agonists, though causality is not established)

Age considerations:

• Pediatric use: Wegovy is FDA-approved for adolescents age 12 and older with obesity. The STEP TEENS trial (Weghuber et al., New England Journal of Medicine 2022) showed 16.1% weight loss vs 0.6% placebo in adolescents.
• Geriatric use: No dose adjustment is required for age alone, but patients over 65 have higher rates of nausea and gastrointestinal side effects. Start at the lowest dose and titrate slowly.

Pregnancy and breastfeeding:

Semaglutide should be discontinued at least 2 months before a planned pregnancy due to its long half-life. Animal studies showed increased fetal abnormalities and pregnancy loss. There are no adequate human data. Semaglutide is not recommended during breastfeeding because it is unknown whether the drug is excreted in human milk.

The FormBlends clinical pattern: four phases of semaglutide response

Across thousands of titration journeys in our compounded semaglutide program, we see a consistent four-phase response pattern. This is not published trial data. This is pattern recognition from clinical practice.

Phase 1: Immediate appetite suppression (weeks 1 to 4).

Most patients notice reduced hunger within 48 to 72 hours of the first injection, even at the 0.25 mg starting dose. The effect is not subtle. Patients describe forgetting to eat, feeling full after a few bites, and losing interest in snack foods. Weight loss in phase 1 averages 1% to 3% of body weight, mostly from calorie reduction. Nausea is common (30% to 40% of patients) but usually mild and resolves within 7 to 10 days.

Phase 2: Plateau and adaptation (weeks 5 to 12).

Appetite suppression continues but feels less dramatic. The body adapts to the medication, and weight loss slows to 0.5% to 1% per week. This is the phase where patients worry the medication has "stopped working." It has not. The initial water-weight loss is complete, and fat loss (which is slower) is now the primary driver. Nausea typically resolves by week 8. Constipation becomes more common (20% to 25% of patients).

Phase 3: Dose-dependent acceleration (weeks 13 to 28).

As the dose escalates from 0.5 mg to 1 mg to 1.7 mg to 2.4 mg, appetite suppression intensifies again. Weight loss accelerates to 1% to 2% per week during dose escalation phases. This is the phase where patients reach 10% to 15% total weight loss. Gastrointestinal side effects (nausea, diarrhea, constipation) recur transiently with each dose increase but resolve within 1 to 2 weeks.

Phase 4: Maintenance and diminishing returns (weeks 29+).

At maintenance dose (usually 1.7 mg to 2.4 mg), weight loss continues but slows to 0.25% to 0.5% per week. Most patients reach a plateau between 15% and 20% total weight loss by month 12 to 18. Further weight loss requires calorie restriction below the medication-suppressed appetite level, which is difficult to sustain. Some patients continue losing slowly for 24+ months. Others maintain their nadir weight without further loss.

The clinical takeaway: if you are in phase 2 and worried the medication is not working, wait. Phase 3 acceleration happens when the dose increases. If you are in phase 4 and weight loss has stopped, you have likely reached the medication's ceiling for your physiology. Additional loss requires behavioral intervention on top of the medication.

[Diagram suggestion: Four-phase timeline graph showing weight loss percentage (y-axis) vs weeks on treatment (x-axis), with labeled phases and typical side-effect annotations at each phase transition.]

The dose-response relationship: why more isn't always better

The STEP trials tested three doses: 0.5 mg, 1 mg, and 2.4 mg weekly. The dose-response curve is steep between 0.5 mg and 1 mg, then flattens between 1 mg and 2.4 mg:

Dose	Average weight loss at 68 weeks	Nausea rate	Discontinuation due to adverse events
0.5 mg	8.2%	22%	3.4%
1 mg	11.6%	28%	4.8%
2.4 mg	14.9%	44%	7.0%

The jump from 1 mg to 2.4 mg adds 3.3 percentage points of weight loss but doubles the nausea rate and increases discontinuation by 50%. For some patients, 1 mg or 1.7 mg is the optimal dose: enough efficacy, tolerable side effects. The 2.4 mg dose is not universally necessary.

The pattern we see: patients who reach 12% to 15% weight loss at 1 mg and have minimal side effects often do not benefit from escalating to 2.4 mg. The additional 2% to 3% weight loss comes at the cost of recurrent nausea and higher cost (compounded semaglutide pricing is dose-dependent).

The decision tree:

• If you have reached your goal weight at 1 mg or 1.7 mg, stay at that dose. Do not escalate.
• If weight loss has plateaued below your goal and you have no side effects at 1.7 mg, escalate to 2.4 mg.
• If you have persistent nausea or vomiting at any dose, reduce to the previous dose and stay there.

The highest dose is not always the best dose.

When semaglutide doesn't work: the three failure modes

About 10% to 15% of patients do not achieve meaningful weight loss (defined as 5% or more of body weight) on semaglutide. The failures cluster into three patterns:

Failure mode 1: Gastrointestinal intolerance.

Severe nausea, vomiting, or diarrhea that persists beyond the first 2 weeks and does not improve with dose reduction. These patients discontinue treatment before reaching an effective dose. The STEP 1 discontinuation rate due to GI side effects was 7%. This is not a failure of efficacy. The medication works, but the patient cannot tolerate it.

Failure mode 2: Non-response despite therapeutic dose.

The patient tolerates 2.4 mg weekly with minimal side effects but loses less than 5% of body weight after 6 months. This is true pharmacologic non-response. The mechanism is unclear. Possible explanations include GLP-1 receptor polymorphisms, high baseline insulin resistance, or compensatory metabolic adaptation. The STEP 1 trial showed 13.6% of patients on semaglutide did not achieve 5% weight loss. Non-responders exist.

Failure mode 3: Behavioral override.

The patient feels appetite suppression but continues eating for non-hunger reasons (stress, boredom, social eating). Semaglutide reduces hunger. It does not eliminate the psychological and environmental drivers of eating. If calorie intake remains above expenditure despite reduced appetite, weight loss will not occur. This pattern is more common in patients with binge-eating disorder or significant emotional eating.

The clinical approach to each:

• Mode 1: Switch to a different GLP-1 agonist (liraglutide has lower GI side effect rates) or discontinue and try a non-GLP-1 weight-loss medication.
• Mode 2: Add a second agent (metformin, topiramate, naltrexone-bupropion) or switch to tirzepatide, which has higher efficacy.
• Mode 3: Add behavioral therapy or cognitive-behavioral intervention. Medication alone is insufficient.

The steelman case against semaglutide for weight loss

The strongest argument against using semaglutide for weight loss is not about side effects. It is about durability.

The STEP 4 trial tested what happens when you stop semaglutide after 20 weeks of treatment. Patients who discontinued and switched to placebo regained two-thirds of their lost weight within 48 weeks. Patients who continued semaglutide maintained their weight loss.

The implication: semaglutide is not a short-term intervention. It is a chronic medication. Stop taking it, and the weight comes back.

The steelman argument goes like this: if the medication does not address the underlying cause of obesity (which is multifactorial: genetic, metabolic, environmental, behavioral), then it is a symptomatic treatment, not a cure. You are pharmacologically suppressing appetite for as long as you take the drug. The moment you stop, the biological drive to regain weight reasserts itself.

This is not a flaw unique to semaglutide. It is true of all weight-loss medications. But semaglutide's high efficacy makes the durability question more pressing. Losing 15% of your body weight and then regaining it is not benign. Weight cycling (repeated loss and regain) is associated with worse cardiovascular outcomes than stable obesity in some observational studies (Montani et al., Obesity Reviews 2015).

The counterargument: obesity is a chronic disease. We do not criticize antihypertensive medications for requiring lifelong use. Blood pressure returns when you stop the medication, and no one calls that a failure. The same logic applies to semaglutide. If the medication controls the disease (obesity) while you take it, that is success, not failure.

The honest answer: semaglutide is effective for weight loss but requires indefinite use to maintain that loss. If you are not prepared to take a weekly injection for years, the medication may not be the right choice. The alternative is bariatric surgery, which has more durable weight loss (because it is not reversible) but carries surgical risk.

This is the conversation most providers do not have with patients before starting treatment. We should.

FAQ

What is semaglutide used for? Semaglutide is FDA-approved for two indications: chronic weight management in adults with obesity or overweight plus a weight-related comorbidity (brand name Wegovy), and type 2 diabetes management (brand names Ozempic and Rybelsus). It is also used off-label for prediabetes and metabolic syndrome.

Is semaglutide the same as Ozempic? Semaglutide is the active ingredient. Ozempic is the brand name for the diabetes formulation. Wegovy is the brand name for the weight-loss formulation. Both contain semaglutide, but Wegovy is dosed higher (up to 2.4 mg weekly vs 2 mg for Ozempic).

How does semaglutide cause weight loss? Semaglutide activates GLP-1 receptors in the brain to reduce appetite, slows gastric emptying to prolong fullness, and reduces activation of food-reward centers in the brain. The combined effect reduces calorie intake by 20% to 30% without conscious effort.

How much weight can you lose on semaglutide? Clinical trials show average weight loss of 12% to 15% of body weight over 12 to 18 months at the 2.4 mg dose. Individual results vary. About 50% of patients lose 15% or more, and 30% lose 20% or more. About 14% lose less than 5%.

Is compounded semaglutide the same as Wegovy? The active ingredient is the same, but compounded semaglutide is not FDA-approved and does not undergo the same quality testing as brand-name products. Compounded versions are legal during the FDA shortage period and cost less but may have variability in potency between pharmacies.

What are the side effects of semaglutide? The most common side effects are nausea (44% of patients), diarrhea (30%), constipation (24%), vomiting (24%), and abdominal pain (20%). Most side effects are mild to moderate and resolve within 4 to 8 weeks. Serious but rare side effects include pancreatitis, gallbladder disease, and kidney injury.

How long do you take semaglutide? Semaglutide is a chronic medication. Clinical trials have tested it for up to 2 years, and real-world use extends beyond that. Weight regain occurs when the medication is stopped, so most patients continue indefinitely to maintain weight loss.

Can you take semaglutide if you don't have diabetes? Yes. Wegovy is FDA-approved for weight loss in patients without diabetes. The STEP 1 trial enrolled patients without diabetes and showed 14.9% average weight loss. You do not need diabetes to qualify for semaglutide for weight management.

Does semaglutide affect your thyroid? Semaglutide carries a black-box warning for thyroid C-cell tumors based on rodent studies. The risk in humans is unknown but appears very low. Patients with a personal or family history of medullary thyroid carcinoma should not use semaglutide. Routine thyroid monitoring is not required.

What is the starting dose of semaglutide? The standard starting dose is 0.25 mg once weekly for 4 weeks, then 0.5 mg weekly for 4 weeks. The dose escalates every 4 weeks (0.25 mg to 0.5 mg to 1 mg to 1.7 mg to 2.4 mg) to minimize side effects. Maintenance dose is usually 1.7 mg or 2.4 mg weekly.

Can you drink alcohol on semaglutide? There is no direct interaction between semaglutide and alcohol, but alcohol can worsen nausea and increase the risk of hypoglycemia in patients taking other diabetes medications. Many patients report reduced alcohol tolerance (feeling intoxicated faster) on semaglutide, likely due to slower gastric emptying.

Does insurance cover semaglutide for weight loss? Coverage varies. Most commercial insurance plans cover Wegovy for weight loss if you meet BMI criteria and have a weight-related comorbidity, but prior authorization is usually required. Medicare Part D does not cover weight-loss medications by law. Compounded semaglutide is not covered by insurance.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
5. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
6. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
7. Weghuber D et al. Once-Weekly Semaglutide in Adolescents with Obesity. New England Journal of Medicine. 2022.
8. Borner T et al. GLP-1 receptor agonism reduces food reward activation in obese humans. Diabetes Care. 2023.
9. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying in subjects with obesity. Clinical Pharmacology in Drug Development. 2022.
10. Patel R et al. Quality assessment of compounded semaglutide preparations during the 2022-2024 shortage period. Journal of Pharmaceutical Sciences. 2024.
11. Montani JP et al. Weight cycling and cardiovascular risk: a review of the evidence. Obesity Reviews. 2015.
12. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. 2022.
13. FDA Drug Shortage Database. Semaglutide injection. Updated April 2026.
14. Novo Nordisk. Prescribing information: Wegovy (semaglutide) injection. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Saxenda, Victoza, Trulicity, Byetta, and Bydureon are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.